$ZBH

Yi Sang sold $66K of ZBH

Yi Sang (Group President, Asia Pacific) sold 800 shares of ZIMMER BIOMET HOLDINGS, INC. (ZBH) at $82.66 on 2026-05-29.

Original reporting
SEC EDGAR · Yi Sang
Published Jun 2, 2026, 8:35 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ZBH
Neutral
medium confidence
Mentioned
$ZBH
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ZBHNeutralLow
01

Why it matters

The disclosure updates the insider activity record but does not introduce new company fundamentals or catalysts.

02

Market read

Traders may monitor for patterns of insider selling, but this single, modest sale is unlikely to drive a major repricing without additional fundamental news.

03

What to watch

Insider sales are often pre-scheduled for liquidity/tax needs; the disclosed sale size ($66k) is small relative to typical institutional flows, limiting price impact.

Relevance 6/10Novelty 6/10Timing: Filed after-hours on 2026-06-02; reflects sale executed 2026-05-29.

Background

SEC Form 4 reports insider transactions (officers/directors/10% owners). This filing documents an open-market sale by Yi Sang, Group President, Asia Pacific.

Company-level read

Ticker impact

$ZBHNeutralMedium confidence
Context

Zimmer Biomet disclosed an officer open-market sale of 800 shares at $82.66 on 2026-05-29 via SEC Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a routine insider transaction datapoint with modest size ($66k) and no accompanying corporate event (earnings, guidance, deal, litigation).

Market effects

Minimal; no sector-wide read-across provided beyond a single-company insider sale.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan could be read as more discretionary selling, potentially increasing near-term caution among short-term traders.

Key entities

  • Zimmer Biomet Holdings, Inc.

    Subject of the SEC Form 4 insider sale by an Asia Pacific officer.

  • Yi Sang

    Group President, Asia Pacific; sold 800 shares on 2026-05-29.

Related articles

$ZBHMedAI 8/10

Zimmer Biomet Holdings, Inc. Q2 2026 Earnings Call Summary

Zimmer Biomet reported Q2 2026 organic constant-currency revenue growth of 4%, led by a 4.6% U.S. increase and 3.1% international growth. Management raised full-year organic guidance to 2.25%-3.25% and adjusted EPS to $8.47-$8.59, including $1B planned 2026 share repurchases. China revenue fell 20%.

$ZBHMedAI 8/10

Zimmer Biomet Q2 Earnings Rise, Lifts FY26 Outlook; Stock Up In Pre-Market

Zimmer Biomet (ZBH) reported Q2 net earnings of $198.3 million, or $1.03 per share, versus $152.8 million, or $0.77 per share, a year earlier. Net sales rose to $2,177.0 million from $2,077.3 million. For FY2026, it raised reported revenue growth to 3.9% to 4.9% and adjusted EPS to $8.47 to $8.59. Shares were up pre-market to $100.15.

$ZBHHighAI 9/10

ZBH's Q2 Earnings Beat, '26 View Raised, Stock Up in Pre-Market

Zimmer Biomet (ZBH) reported Q2 2026 adjusted EPS of $2.07, above the $2.01 consensus, and net sales of $2.18B, above the $2.13B estimate. GAAP EPS was $1.03. The company raised 2026 guidance, including revenue growth to 3.9% to 4.9% and adjusted EPS to $8.47 to $8.59. Shares rose 1.4% pre-market.

$ZBHHighAI 9/10

[ZBH Q2 2026 Earnings Call] Zimmer Biomet Beats and Raises as Hip, Tech Sales Surge; U.S. Technology Revenue Jumps 53% — BigGo Finance

Zimmer Biomet (ZBH) reported Q2 2026 net sales of $2.177B (+4.8%) and GAAP diluted EPS of $1.03 (+33.8%), with technology sales up 53% in the U.S. Hip sales grew about 6% and knees were nearly flat. The company raised 2026 organic revenue growth to 2.25%–3.25% and adjusted EPS to $8.47–$8.59, and plans up to $1B buybacks.